Krazati Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10689377 MIRATI THERAPS KRas G12C inhibitors
May, 2037

(12 years from now)

Krazati is a drug owned by Mirati Therapeutics Inc. It is used for treating locally advanced or metastatic non-small cell lung cancer in adult patients with a specific KRAS mutation who have already undergone prior systemic therapy. Krazati uses Adagrasib as an active ingredient. Krazati was launched by Mirati Theraps in 2022. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 17, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 12, 2027
Orphan Drug Exclusivity(ODE-352) Dec 12, 2029

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ADAGRASIB ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 12 December, 2022

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...

Dosage: TABLET

More Information on Dosage

KRAZATI family patents

Family Patents